SOUTH SAN FRANCISCO, Calif., May 12, 2026
Encoded Therapeutics announced new preclinical findings at the 2026 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting highlighting significant progress across its precision vector engineering platform for severe neurological disorders. The company presented new data supporting advancement of multiple gene therapy programs, including ETX301 for chronic neuropathic pain and a novel Angelman syndrome gene therapy candidate, reinforcing growing industry momentum behind next-generation precision genetic medicines targeting diseases of the central and peripheral nervous systems. Encoded stated that its proprietary platform combines engineered regulatory elements, optimized AAV vectors, and vectorized microRNA technologies to achieve highly selective gene modulation while minimizing off-target effects. The latest ASGCT 2026 data further position the company as an emerging leader in precision neurology-focused gene therapy development.
Encoded Advances Precision Gene Therapy for Chronic Pain
One of the key presentations at ASGCT 2026 focused on NociPro, Encoded’s proprietary promoter platform designed to selectively target pain-sensing nociceptive neurons within the dorsal root ganglia (DRG). The platform serves as a core component of ETX301, the company’s investigational one-time gene therapy candidate being developed for post-amputation neuroma pain, a severe and difficult-to-treat form of chronic neuropathic pain. According to Encoded, preclinical studies across rodents, human iPSC-derived neurons, and non-human primates demonstrated that NociPro achieved highly selective targeting of nociceptor sensory neurons while avoiding detectable expression in the central nervous system. The company reported that when paired with vectorized microRNA targeting SCN9A (NaV1.7), the therapy produced strong and durable reduction of pain-signaling protein expression with improved tolerability compared with broader non-selective promoter systems.
Encoded stated that the new findings reinforce the therapeutic potential of ETX301 as a non-opioid gene therapy approach for chronic pain management, an area receiving increasing attention as healthcare systems seek alternatives to long-term opioid treatment. The company recently nominated ETX301 as a formal development candidate and plans to submit an Investigational New Drug (IND) application in 2027. Researchers believe selective NaV1.7 suppression could provide long-lasting pain reduction without many of the safety and dependency concerns associated with conventional opioid-based therapies. The latest ASGCT data also demonstrated that Encoded’s vector engineering platform can maintain strong therapeutic potency while significantly improving cell-type specificity, a major challenge historically limiting broader application of neurological gene therapies.
Angelman Syndrome Program Demonstrates Broad Brain Delivery
Encoded also presented important preclinical proof-of-concept data for its investigational Angelman syndrome gene therapy program, which uses an intravenously delivered AAV-miRNA platform designed to unsilence the UBE3A gene, the underlying genetic driver of Angelman syndrome. According to the company, the therapy combined an optimized vectorized microRNA payload with an externally developed blood-brain-barrier-crossing AAV capsid to achieve broad neuronal transduction across multiple disease-relevant brain regions in non-human primates. Researchers observed approximately 57% increased UBE3A expression and a 24% increase in UBE3A protein levels in regions including the cortex, hippocampus, and thalamus following a single administration. The company also reported favorable tolerability throughout a 60-day preclinical study with no significant adverse findings observed.
Advertisement
The Angelman syndrome data highlight Encoded’s broader strategy to develop one-time precision genetic medicines capable of addressing underlying disease biology rather than simply managing symptoms. Angelman syndrome is a rare neurodevelopmental disorder characterized by severe developmental delay, intellectual disability, speech impairment, seizures, and motor dysfunction. Current treatment options remain limited and primarily supportive. Industry analysts believe advances in blood-brain-barrier-penetrating AAV vectors and selective gene regulation technologies may significantly expand opportunities for CNS-targeted gene therapies over the coming decade. Encoded’s approach aims to combine durable therapeutic activity with improved cellular specificity and scalable systemic administration.
Encoded Strengthens Position in Neurology Gene Therapy Market
The latest ASGCT 2026 presentations reflect Encoded Therapeutics’ broader strategy to establish itself as a leader in precision neurological gene therapy development. In addition to its expanding preclinical pipeline, the company is currently advancing ETX101, an investigational AAV9-based gene regulation therapy for Dravet syndrome, into pivotal-stage clinical development. ETX101 recently received multiple regulatory designations from the U.S. Food and Drug Administration, including Breakthrough Therapy, RMAT, Fast Track, Rare Pediatric Disease, and Orphan Drug designations, highlighting the growing regulatory support for transformative neurological gene therapies.
Encoded executives stated that the ASGCT presentations demonstrate the versatility of the company’s vector engineering platform across both rare monogenic disorders and broader neurological diseases with large unmet medical need. The company’s integrated discovery, development, and in-house GMP manufacturing capabilities are designed to accelerate advancement of multiple precision gene therapy programs simultaneously. As investment in CNS-focused genetic medicines continues rising globally, Encoded aims to differentiate its platform through highly selective gene regulation, cell-type precision, and durable one-time treatment approaches capable of addressing complex neurological disease mechanisms.
Source: Encoded Therapeutics press release
